Exosome-Based COVID-19 Vaccine.
Methods Mol Biol
; 2668: 301-311, 2023.
Article
in English
| MEDLINE | ID: covidwho-2316082
ABSTRACT
Extracellular vesicles (EVs) enable cell-to-cell communication and, by delivering antigens, can stimulate the immune response strongly. Approved in use SARS-CoV-2 vaccine, candidates immunize with the viral spike protein delivered via viral vectors, translated by injected mRNAs, or as a pure protein. Here, we outline a novel methodological approach for generating SARS-CoV-2 vaccine using exosome that delivers antigens from the SARS-CoV-2 structural proteins. Engineered EVs can be loaded with viral antigens, thus acting as antigens presenting EVs, eliciting strong and targeted CD8(+) T cell and B cell, offering a unique approach to vaccine development. Engineered EVs thus portray a safe, adaptable, and effective approach for a virus-free vaccine development.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Exosomes
/
Extracellular Vesicles
/
COVID-19
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Methods Mol Biol
Journal subject:
Molecular Biology
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS